CPT code 83880 represents a quantitative laboratory assay for natriuretic peptide, a hormone released by cardiac muscle in response to increased wall stress. This biomarker is clinically important for diagnosing and managing congestive heart failure and is widely used in emergency, inpatient, and outpatient settings. Nationally, the test influences care pathways for patients presenting with dyspnea and contributes to risk stratification and treatment decisions in heart failure management.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the test’s clinical role and typical sites of service, along with coverage and reimbursement context across major payers. The publication summarizes common billing modifiers and related administrative considerations, presents benchmarks where available, and highlights policy updates that affect laboratory reimbursement and coding practice.

This report is intended for billing managers, laboratory directors, clinicians involved in heart failure care, and policy analysts seeking a clear, national-level briefing on the use and payer handling of CPT code 83880. Data not available in the input is noted where applicable.